nach oben

Erschienen in:

01.12.2010 | Research Article

Treatment of experimental periodontal disease by a selective inhibitor of cyclooxygenase-2 with scaling and root planing (SRP)

verfasst von: Valdir Gouveia Garcia, Rodrigo Yuji Takano, Leandro Araújo Fernandes, Juliano Milanezi de Almeida, Leticia Helena Theodoro

Erschienen in: Inflammopharmacology | Ausgabe 6/2010

Einloggen, um Zugang zu erhalten

Abstract

Lumiracoxib is a selective inhibitor of cyclooxygenase-2 (COX-2) approved for the relief of symptoms of chronic inflammatory conditions. The aim of this study was to evaluate the effects of this specific inhibitor of COX-2 as adjunctive treatment on induced periodontitis in rats. Periodontal disease was induced at the first mandibular molar of 60 rats. After 7 days, the ligature was removed and all animals were submitted to scaling and root planing (SRP) along with local irrigation with saline solution and were divided into 2 groups: SRP (n = 30)—received subcutaneous injections of 1 mg/kg of body weight/day of saline solution for 3 days and; SRP + L (n = 30)—received subcutaneous injections of 1 mg/kg of body weight/day of Lumiracoxib for 3 days. Ten animals in each group were killed at 7, 15, and 30 days. The histological description was performed and the histometric values were statistically analyzed. In Group SRP + L, the histometric analysis (0.58 ± 0.08, 0.64 ± 0.06, and 0.56 ± 0.10 mm²) showed less bone loss (p < 0.05) than Group SRP (1.52 ± 0.08, 1.55 ± 0.09, and 1.49 ± 0.24 mm²) at 7, 15, and 30 days, respectively. Within the limits of this study it can be concluded that subcutaneous application of specific inhibitor of COX-2 was a beneficial adjunctive treatment for periodontal diseases induced in rats.

Azoubel MC, Menezes AM, Bezerra D et al (2007) Comparison of etoricoxib and indomethacin for the treatment of experimental periodontitis in rats. Braz J Med Biol Res 40:117–125PubMed

Azoubel MC, Sarmento VA, Cangussú V (2008) Adjunctive benefits of etoricoxib in non-surgical treatment of aggressive periodontitis—short-term evaluation. J Periodontol 79:1719–1725CrossRefPubMed

Bezerra MM, de Lima V, Alencar VB (2000) Selective cyclooxygenase-2 inhibition prevents alveolar bone loss in experimental periodontitis in rats. J Periodontol 71:1009–1014CrossRefPubMed

Bissada NF, Ng VW (1998) Clinical evaluation of systemic doxycycline and ibuprofen administration as an adjunctive treatment for adult periodontitis. J Periodontol 69:772–776PubMed

Cavagni J, Soletti AC, Gaio EG et al (2005) The effect of dexamethasone in the pathogenesis of ligature-induced periodontal disease in Wistar rats. Braz Oral Res 19:290–294CrossRefPubMed

Chandrasekharan NV, Dai H, Roos KL (2002) COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA 99:13926–13931CrossRefPubMed

Crotti T, Smith MD, Hirsch R et al (2003) Receptor activator NF kappaB ligand (RANKL) and osteoprotegerin (OPG) protein expression in periodontitis. J Periodontal Res 38:380–387PubMed

De Almeida JM, Theodoro LH, Bosco AF et al (2008) Treatment of experimental periodontal disease by photodynamic therapy in rats with diabetes. J Periodontol 79:2156–2165CrossRefPubMed

Engelhardt G (1996) Pharmacology of meloxicam, a new non-steroidal anti-inflammatory drug with an improved safety profile through preferential inhibition of COX-2. Br J Rheumatol 35:4–12PubMed

Fleischmann R, Sheldon E, Maldonado-Cocco J et al (2006) Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a prospective randomized 13-week study versus placebo and celecoxib. Clin Rheumatol 25:42–53CrossRefPubMed

Furlaneto FA, Nagata MJ, Fucini SE et al (2007) Bone healing in critical-size defects treated with bioactive glass/calcium sulfate: a histologic and histometric study in rat calvaria. Clin Oral Implants Res 18:311–318CrossRefPubMed

Haffajee AD, Cugini MA, Dibart S et al (1997) The effect of SRP on the clinical and microbiological parameters of periodontal diseases. J Clin Periodontol 24:324–334CrossRefPubMed

Hilário MOE, Terreri MT, Len CA (2006) Nonsteroidal anti-inflammatories, COX 2 inhibitors, indications, adverse effects. J Pediatric 82:206–212CrossRef

Hofbauer LC, Lacey DL, Dunstan CR et al (1999) Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 25:255–259CrossRefPubMed

Holanda Pinto SA, Pinto LM, Cunha GM et al (2008) Anti-inflammatory effect of alpha, beta-amyrin, a pentacyclic triterpene from Protium heptaphyllum in rat model of acute periodontitis. Inflammopharmacology 16:48–52CrossRefPubMed

Holzhausen M, Rossa C Jr, Marcantonio E Jr et al (2002) Effect of selective cyclooxygenase-2 inhibition on the development of ligature-induced periodontitis in rats. J Periodontol 73:1030–1036CrossRefPubMed

Li KL, Vogel R, Jeffcoat MK (1996) The effect of ketoprofen creams on periodontal disease in rhesus monkeys. J Periodontol Res 31:525–532CrossRef

Liu D, Xu JK, Figliomeni L et al (2003) Expression of RANKL and OPG mRNA in periodontal disease: possible involvement in bone destruction. Int J Mol Med 11:17–21PubMed

Lohinai Z, Stachlewitz R, Szekely AD et al (2001) Evidence for the expression of cyclooxygenase-2 enzyme in periodontitis. Life Sci 70:279–290CrossRefPubMed

Mangold JB, Gu H, Rodriguez LC et al (2004) Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects. Drug Metab Dispos 32:566–571CrossRefPubMed

Meisel P, Kocher T (2005) Photodynamic therapy for periodontal diseases: state of the art. J Photochem Photobiol B 79:159–170CrossRefPubMed

Mitchell JA, Larkin S, Williams TJ (1995) Cyclooxygenase 2: regulation and relevance in inflammation. Biochem Pharmacol 5:1535–1542CrossRef

Miyauchi M, Hiraoka M, Oka H (2004) Immuno- localization of COX-1 and COX-2 in the rat molar periodontal tissue after topical application of lipopolysaccharide. Arch Oral Biol 49:739–746CrossRefPubMed

Morton RS, Dongari-Bagtzoglou AI (2001) Cyclooxygenase-2 is upregulated in inflamed gingival tissues. J Periodontol 72:461–469CrossRefPubMed

Mousques T, Listgarten M, Phillips R (1980) Effect of scaling and root planning on the composition of the human subgingival microbial flora. J Periodontal Res 15:144–151CrossRefPubMed

Nogueira-Filho GR, Rosa BT, César-Neto JB et al (2007) Low- and high-yield cigarette smoke inhalation potentiates bone loss during ligature-induced periodontitis. J Periodontol 78:730–735CrossRef

Nyman S, Schroeder HE, Lindhe J (1979) Suppression of Inflammation and bone resorption by indomethacin during experimental periodontitis in dogs. J Periodontol 50:450–461CrossRefPubMed

Offenbacher S, Heasman PA, Collins JG (1993) Modulation of host PGE2 secretion as a determinant of periodontal disease expression. J Periodontol 64:432–444PubMed

Oliveira TM, Sakai VT, Machado MA (2008) COX-2 inhibition decreases VEGF expression and alveolar bone loss during the progression of experimental periodontitis in rats. J Periodontol 79:1062–1069CrossRefPubMed

Page RC (2002) The etiology and pathogenesis of periodontitis. Compend Contin Educ Dent 23:11–14PubMed

Paquette DW, Williams RC (2000) Modulation of host inflammatory mediators as a treatment strategy for periodontal diseases. Periodontology 24:239–252CrossRef

Petersilka GJ, Ehmke B, Flemming TF (2002) Antimicrobial effects of mechanical debridement. Periodontol 2000 28:56–71

Rordorf CM, Choi L, Marshall P et al (2005) Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet 44:247–1266CrossRef

Sato Y, Arai N, Negishi A et al (1997) Expression of cyclooxygenase genes and involvement of endogenous prostaglandin during osteogenesis in the rat tibial bone marrow cavity. J Med Dent Sci 44:81–92PubMed

Taiyeb Ali TB, Waite IM (1993) The effect of systemic ibuprofen on gingival inflammation in humans. J Clin Periodontol 20:723–728CrossRefPubMed

Umeda M, Takeuchi Y, Noguchi K et al (2004) Effects of non-surgical periodontal therapy on the microbiota. Periodontol 2000 36:98–120CrossRefPubMed

Weaks-Dybvig M, Sanavi F, Zander H et al (1982) The effect of indomethacin on alveolar bone loss in experimental periodontitis. J Periodontol Res 17:90–100CrossRef

Williams RC, Paquette DW (2000) Understanding the pathogenesis of periodontitis: a century of discovery. J Int Acad Periodontol 2:59–63PubMed

Williams R, Jeffcoat MK, Howell TH (1988) Ibuprofen: an inhibitor of treatment of alveolar bone resorption in beagles. J Periodontol Res 23:225–229CrossRef

Ximenez-Fyvie LA, Haffajee AD, Socransky SS (2000) Microbial composition of supra- and subgingival plaque in subjects with adult periodontitis. J Clin Periodontol 27:722–732CrossRefPubMed

Yen CA, Damoulis PD, Stark PC et al (2008) The effect of a selective cyclooxygenase-2 inhibitor (celecoxib) on chronic periodontitis. J Periodontol 79:104–113CrossRefPubMed

Zhang X, Schqarz EM, Young DA et al (2002) Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J Clin Invest 110:1211CrossRef

Zubery Y, Dunstan CR, Story BM (1998) Bone resorption caused by three periodontal pathogens in vivo in mice is mediated in part by prostaglandin. Infect Immun 66:4158–4162PubMed

Titel: Treatment of experimental periodontal disease by a selective inhibitor of cyclooxygenase-2 with scaling and root planing (SRP)
verfasst von: Valdir Gouveia Garcia
Rodrigo Yuji Takano
Leandro Araújo Fernandes
Juliano Milanezi de Almeida
Leticia Helena Theodoro
Publikationsdatum: 01.12.2010
Verlag: SP Birkhäuser Verlag Basel
Erschienen in: Inflammopharmacology / Ausgabe 6/2010
Print ISSN: 0925-4692
Elektronische ISSN: 1568-5608
DOI: https://doi.org/10.1007/s10787-010-0059-z

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2010

The sad plight of multiple sclerosis research (low on fact, high on fiction): critical data to support it being a neurocristopathy

Concerning: “The sad plight of multiple sclerosis research (low on fact, high on fiction): critical data to support it being a neurocristopathy” by Peter O. Behan and Abhijit Chaudhuri

Quo vadis multiple sclerosis?

Antihypercholesterolaemic effect of ginger rhizome (Zingiber officinale) in rats

Atorvastatin exhibits anti-inflammatory and anti-oxidant properties in adjuvant-induced monoarthritis

Erratum to: The sad plight of multiple sclerosis research (low on fact, high on fiction): critical data to support it being a neurocristopathy